nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP2D6—Gefitinib—lung cancer	0.0401	0.229	CbGbCtD
Duloxetine—CYP2D6—Vinorelbine—lung cancer	0.0309	0.176	CbGbCtD
Duloxetine—CYP1A2—Erlotinib—lung cancer	0.0288	0.164	CbGbCtD
Duloxetine—CYP2D6—Erlotinib—lung cancer	0.0237	0.135	CbGbCtD
Duloxetine—CYP1A2—Etoposide—lung cancer	0.0208	0.119	CbGbCtD
Duloxetine—HTR2A—phrenic nerve—lung cancer	0.0192	0.4	CbGeAlD
Duloxetine—CYP2D6—Vinblastine—lung cancer	0.019	0.109	CbGbCtD
Duloxetine—CYP2D6—Doxorubicin—lung cancer	0.0117	0.0668	CbGbCtD
Duloxetine—HTR2A—pulmonary artery—lung cancer	0.00696	0.145	CbGeAlD
Duloxetine—NPY1R—lung—lung cancer	0.00305	0.0635	CbGeAlD
Duloxetine—SLC6A3—respiratory system—lung cancer	0.00241	0.0503	CbGeAlD
Duloxetine—SLC6A4—respiratory system—lung cancer	0.00221	0.0461	CbGeAlD
Duloxetine—NPY1R—lymph node—lung cancer	0.00208	0.0434	CbGeAlD
Duloxetine—SLC6A2—respiratory system—lung cancer	0.00195	0.0406	CbGeAlD
Duloxetine—CYP1A2—respiratory system—lung cancer	0.0015	0.0312	CbGeAlD
Duloxetine—SLC6A3—lung—lung cancer	0.00128	0.0267	CbGeAlD
Duloxetine—SLC6A4—lung—lung cancer	0.00117	0.0245	CbGeAlD
Duloxetine—HTR2A—respiratory system—lung cancer	0.00117	0.0244	CbGeAlD
Duloxetine—SLC6A2—lung—lung cancer	0.00103	0.0216	CbGeAlD
Duloxetine—HTR2A—epithelium—lung cancer	0.000978	0.0204	CbGeAlD
Duloxetine—HTR2A—trachea—lung cancer	0.000865	0.018	CbGeAlD
Duloxetine—CYP1A2—lung—lung cancer	0.000795	0.0166	CbGeAlD
Duloxetine—SLC6A2—lymph node—lung cancer	0.000707	0.0147	CbGeAlD
Duloxetine—HTR2A—lung—lung cancer	0.000621	0.013	CbGeAlD
Duloxetine—Protriptyline—ABCB1—lung cancer	0.000456	0.278	CrCbGaD
Duloxetine—Propranolol—CYP1A1—lung cancer	0.000358	0.218	CrCbGaD
Duloxetine—Fluoxetine—ALB—lung cancer	0.000326	0.199	CrCbGaD
Duloxetine—Fluoxetine—ABCB1—lung cancer	0.000311	0.19	CrCbGaD
Duloxetine—Propranolol—ABCB1—lung cancer	0.00019	0.116	CrCbGaD
Duloxetine—Constipation—Paclitaxel—lung cancer	0.000179	0.000314	CcSEcCtD
Duloxetine—Pain—Paclitaxel—lung cancer	0.000179	0.000314	CcSEcCtD
Duloxetine—Confusional state—Docetaxel—lung cancer	0.000178	0.000314	CcSEcCtD
Duloxetine—Pharyngitis—Methotrexate—lung cancer	0.000178	0.000314	CcSEcCtD
Duloxetine—Urinary tract disorder—Methotrexate—lung cancer	0.000177	0.000312	CcSEcCtD
Duloxetine—Photosensitivity reaction—Doxorubicin—lung cancer	0.000177	0.000312	CcSEcCtD
Duloxetine—Oedema—Docetaxel—lung cancer	0.000177	0.000312	CcSEcCtD
Duloxetine—Anaphylactic shock—Docetaxel—lung cancer	0.000177	0.000312	CcSEcCtD
Duloxetine—Weight increased—Doxorubicin—lung cancer	0.000177	0.000311	CcSEcCtD
Duloxetine—Pruritus—Gemcitabine—lung cancer	0.000176	0.000311	CcSEcCtD
Duloxetine—Urethral disorder—Methotrexate—lung cancer	0.000176	0.00031	CcSEcCtD
Duloxetine—Infection—Docetaxel—lung cancer	0.000176	0.00031	CcSEcCtD
Duloxetine—Weight decreased—Doxorubicin—lung cancer	0.000176	0.000309	CcSEcCtD
Duloxetine—Feeling abnormal—Etoposide—lung cancer	0.000175	0.000309	CcSEcCtD
Duloxetine—Hyperglycaemia—Doxorubicin—lung cancer	0.000175	0.000308	CcSEcCtD
Duloxetine—Diarrhoea—Irinotecan—lung cancer	0.000175	0.000308	CcSEcCtD
Duloxetine—Gastrointestinal pain—Etoposide—lung cancer	0.000174	0.000307	CcSEcCtD
Duloxetine—Shock—Docetaxel—lung cancer	0.000174	0.000307	CcSEcCtD
Duloxetine—Nervous system disorder—Docetaxel—lung cancer	0.000174	0.000306	CcSEcCtD
Duloxetine—Thrombocytopenia—Docetaxel—lung cancer	0.000173	0.000305	CcSEcCtD
Duloxetine—Infestation NOS—Doxorubicin—lung cancer	0.000173	0.000305	CcSEcCtD
Duloxetine—Infestation—Doxorubicin—lung cancer	0.000173	0.000305	CcSEcCtD
Duloxetine—Visual impairment—Methotrexate—lung cancer	0.000173	0.000305	CcSEcCtD
Duloxetine—Tachycardia—Docetaxel—lung cancer	0.000173	0.000304	CcSEcCtD
Duloxetine—Feeling abnormal—Paclitaxel—lung cancer	0.000172	0.000303	CcSEcCtD
Duloxetine—Skin disorder—Docetaxel—lung cancer	0.000172	0.000303	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Doxorubicin—lung cancer	0.000172	0.000302	CcSEcCtD
Duloxetine—Hypersensitivity—Cisplatin—lung cancer	0.000171	0.000301	CcSEcCtD
Duloxetine—Gastrointestinal pain—Paclitaxel—lung cancer	0.000171	0.000301	CcSEcCtD
Duloxetine—Diarrhoea—Gemcitabine—lung cancer	0.000171	0.0003	CcSEcCtD
Duloxetine—Renal failure—Doxorubicin—lung cancer	0.00017	0.0003	CcSEcCtD
Duloxetine—Erythema multiforme—Methotrexate—lung cancer	0.00017	0.000299	CcSEcCtD
Duloxetine—Dizziness—Irinotecan—lung cancer	0.000169	0.000298	CcSEcCtD
Duloxetine—Urticaria—Etoposide—lung cancer	0.000169	0.000298	CcSEcCtD
Duloxetine—Jaundice—Doxorubicin—lung cancer	0.000169	0.000297	CcSEcCtD
Duloxetine—Stomatitis—Doxorubicin—lung cancer	0.000169	0.000297	CcSEcCtD
Duloxetine—Anorexia—Docetaxel—lung cancer	0.000169	0.000297	CcSEcCtD
Duloxetine—Body temperature increased—Etoposide—lung cancer	0.000168	0.000296	CcSEcCtD
Duloxetine—Abdominal pain—Etoposide—lung cancer	0.000168	0.000296	CcSEcCtD
Duloxetine—Conjunctivitis—Doxorubicin—lung cancer	0.000168	0.000296	CcSEcCtD
Duloxetine—Urinary tract infection—Doxorubicin—lung cancer	0.000168	0.000296	CcSEcCtD
Duloxetine—Eye disorder—Methotrexate—lung cancer	0.000168	0.000295	CcSEcCtD
Duloxetine—Tinnitus—Methotrexate—lung cancer	0.000167	0.000295	CcSEcCtD
Duloxetine—Asthenia—Cisplatin—lung cancer	0.000167	0.000294	CcSEcCtD
Duloxetine—Cardiac disorder—Methotrexate—lung cancer	0.000167	0.000293	CcSEcCtD
Duloxetine—Urticaria—Paclitaxel—lung cancer	0.000166	0.000292	CcSEcCtD
Duloxetine—Abdominal pain—Paclitaxel—lung cancer	0.000165	0.000291	CcSEcCtD
Duloxetine—Body temperature increased—Paclitaxel—lung cancer	0.000165	0.000291	CcSEcCtD
Duloxetine—Hepatobiliary disease—Doxorubicin—lung cancer	0.000164	0.000288	CcSEcCtD
Duloxetine—Epistaxis—Doxorubicin—lung cancer	0.000163	0.000288	CcSEcCtD
Duloxetine—Angiopathy—Methotrexate—lung cancer	0.000163	0.000287	CcSEcCtD
Duloxetine—Vomiting—Irinotecan—lung cancer	0.000163	0.000287	CcSEcCtD
Duloxetine—Immune system disorder—Methotrexate—lung cancer	0.000162	0.000285	CcSEcCtD
Duloxetine—Mediastinal disorder—Methotrexate—lung cancer	0.000162	0.000285	CcSEcCtD
Duloxetine—Rash—Irinotecan—lung cancer	0.000161	0.000284	CcSEcCtD
Duloxetine—Dermatitis—Irinotecan—lung cancer	0.000161	0.000284	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000161	0.000284	CcSEcCtD
Duloxetine—Chills—Methotrexate—lung cancer	0.000161	0.000284	CcSEcCtD
Duloxetine—Headache—Irinotecan—lung cancer	0.00016	0.000282	CcSEcCtD
Duloxetine—Insomnia—Docetaxel—lung cancer	0.00016	0.000282	CcSEcCtD
Duloxetine—Diarrhoea—Cisplatin—lung cancer	0.000159	0.00028	CcSEcCtD
Duloxetine—Paraesthesia—Docetaxel—lung cancer	0.000159	0.00028	CcSEcCtD
Duloxetine—Alopecia—Methotrexate—lung cancer	0.000159	0.000279	CcSEcCtD
Duloxetine—Vomiting—Gemcitabine—lung cancer	0.000159	0.000279	CcSEcCtD
Duloxetine—Somnolence—Docetaxel—lung cancer	0.000157	0.000277	CcSEcCtD
Duloxetine—Mental disorder—Methotrexate—lung cancer	0.000157	0.000277	CcSEcCtD
Duloxetine—Rash—Gemcitabine—lung cancer	0.000157	0.000277	CcSEcCtD
Duloxetine—Dermatitis—Gemcitabine—lung cancer	0.000157	0.000277	CcSEcCtD
Duloxetine—Hypersensitivity—Etoposide—lung cancer	0.000157	0.000276	CcSEcCtD
Duloxetine—Malnutrition—Methotrexate—lung cancer	0.000156	0.000275	CcSEcCtD
Duloxetine—Erythema—Methotrexate—lung cancer	0.000156	0.000275	CcSEcCtD
Duloxetine—Haemoglobin—Doxorubicin—lung cancer	0.000156	0.000275	CcSEcCtD
Duloxetine—Headache—Gemcitabine—lung cancer	0.000156	0.000275	CcSEcCtD
Duloxetine—Dyspepsia—Docetaxel—lung cancer	0.000156	0.000274	CcSEcCtD
Duloxetine—Haemorrhage—Doxorubicin—lung cancer	0.000155	0.000274	CcSEcCtD
Duloxetine—Hepatitis—Doxorubicin—lung cancer	0.000155	0.000274	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—lung cancer	0.000155	0.000272	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—lung cancer	0.000154	0.000272	CcSEcCtD
Duloxetine—Decreased appetite—Docetaxel—lung cancer	0.000154	0.000271	CcSEcCtD
Duloxetine—Hypersensitivity—Paclitaxel—lung cancer	0.000154	0.000271	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—lung cancer	0.000154	0.00027	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—lung cancer	0.000153	0.00027	CcSEcCtD
Duloxetine—Dysgeusia—Methotrexate—lung cancer	0.000153	0.000269	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000153	0.000269	CcSEcCtD
Duloxetine—Asthenia—Etoposide—lung cancer	0.000153	0.000269	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—lung cancer	0.000153	0.000269	CcSEcCtD
Duloxetine—Fatigue—Docetaxel—lung cancer	0.000153	0.000269	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—lung cancer	0.000152	0.000268	CcSEcCtD
Duloxetine—Nausea—Irinotecan—lung cancer	0.000152	0.000268	CcSEcCtD
Duloxetine—Constipation—Docetaxel—lung cancer	0.000151	0.000266	CcSEcCtD
Duloxetine—Pain—Docetaxel—lung cancer	0.000151	0.000266	CcSEcCtD
Duloxetine—Back pain—Methotrexate—lung cancer	0.000151	0.000266	CcSEcCtD
Duloxetine—Pruritus—Etoposide—lung cancer	0.000151	0.000265	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—lung cancer	0.00015	0.000264	CcSEcCtD
Duloxetine—Asthenia—Paclitaxel—lung cancer	0.00015	0.000264	CcSEcCtD
Duloxetine—Nausea—Gemcitabine—lung cancer	0.000148	0.000261	CcSEcCtD
Duloxetine—Vomiting—Cisplatin—lung cancer	0.000148	0.00026	CcSEcCtD
Duloxetine—Pruritus—Paclitaxel—lung cancer	0.000148	0.00026	CcSEcCtD
Duloxetine—Vision blurred—Methotrexate—lung cancer	0.000147	0.000259	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—lung cancer	0.000147	0.000259	CcSEcCtD
Duloxetine—Rash—Cisplatin—lung cancer	0.000147	0.000258	CcSEcCtD
Duloxetine—Dermatitis—Cisplatin—lung cancer	0.000146	0.000258	CcSEcCtD
Duloxetine—Feeling abnormal—Docetaxel—lung cancer	0.000146	0.000257	CcSEcCtD
Duloxetine—Diarrhoea—Etoposide—lung cancer	0.000146	0.000257	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—lung cancer	0.000145	0.000256	CcSEcCtD
Duloxetine—Ill-defined disorder—Methotrexate—lung cancer	0.000145	0.000255	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—lung cancer	0.000145	0.000255	CcSEcCtD
Duloxetine—Gastrointestinal pain—Docetaxel—lung cancer	0.000145	0.000255	CcSEcCtD
Duloxetine—Anaemia—Methotrexate—lung cancer	0.000144	0.000254	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—lung cancer	0.000144	0.000254	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—lung cancer	0.000144	0.000254	CcSEcCtD
Duloxetine—Diarrhoea—Paclitaxel—lung cancer	0.000143	0.000252	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—lung cancer	0.000141	0.000248	CcSEcCtD
Duloxetine—Malaise—Methotrexate—lung cancer	0.000141	0.000248	CcSEcCtD
Duloxetine—Dizziness—Etoposide—lung cancer	0.000141	0.000248	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—lung cancer	0.00014	0.000247	CcSEcCtD
Duloxetine—Vertigo—Methotrexate—lung cancer	0.00014	0.000247	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—lung cancer	0.00014	0.000247	CcSEcCtD
Duloxetine—Abdominal pain—Docetaxel—lung cancer	0.00014	0.000246	CcSEcCtD
Duloxetine—Body temperature increased—Docetaxel—lung cancer	0.00014	0.000246	CcSEcCtD
Duloxetine—Leukopenia—Methotrexate—lung cancer	0.00014	0.000246	CcSEcCtD
Duloxetine—Chills—Doxorubicin—lung cancer	0.00014	0.000246	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—lung cancer	0.000139	0.000244	CcSEcCtD
Duloxetine—Dizziness—Paclitaxel—lung cancer	0.000138	0.000243	CcSEcCtD
Duloxetine—Nausea—Cisplatin—lung cancer	0.000138	0.000243	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—lung cancer	0.000137	0.000242	CcSEcCtD
Duloxetine—Cough—Methotrexate—lung cancer	0.000136	0.00024	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—lung cancer	0.000136	0.00024	CcSEcCtD
Duloxetine—Convulsion—Methotrexate—lung cancer	0.000135	0.000238	CcSEcCtD
Duloxetine—Vomiting—Etoposide—lung cancer	0.000135	0.000238	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—lung cancer	0.000135	0.000238	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—lung cancer	0.000135	0.000238	CcSEcCtD
Duloxetine—Rash—Etoposide—lung cancer	0.000134	0.000236	CcSEcCtD
Duloxetine—Dermatitis—Etoposide—lung cancer	0.000134	0.000236	CcSEcCtD
Duloxetine—Headache—Etoposide—lung cancer	0.000133	0.000235	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—lung cancer	0.000133	0.000235	CcSEcCtD
Duloxetine—Myalgia—Methotrexate—lung cancer	0.000133	0.000234	CcSEcCtD
Duloxetine—Arthralgia—Methotrexate—lung cancer	0.000133	0.000234	CcSEcCtD
Duloxetine—Chest pain—Methotrexate—lung cancer	0.000133	0.000234	CcSEcCtD
Duloxetine—Tension—Doxorubicin—lung cancer	0.000133	0.000234	CcSEcCtD
Duloxetine—Vomiting—Paclitaxel—lung cancer	0.000133	0.000234	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—lung cancer	0.000133	0.000233	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000132	0.000233	CcSEcCtD
Duloxetine—Rash—Paclitaxel—lung cancer	0.000132	0.000232	CcSEcCtD
Duloxetine—Dermatitis—Paclitaxel—lung cancer	0.000132	0.000232	CcSEcCtD
Duloxetine—Discomfort—Methotrexate—lung cancer	0.000131	0.000231	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—lung cancer	0.000131	0.000231	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—lung cancer	0.000131	0.00023	CcSEcCtD
Duloxetine—Headache—Paclitaxel—lung cancer	0.000131	0.00023	CcSEcCtD
Duloxetine—Hypersensitivity—Docetaxel—lung cancer	0.00013	0.00023	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—lung cancer	0.00013	0.000229	CcSEcCtD
Duloxetine—Confusional state—Methotrexate—lung cancer	0.000129	0.000226	CcSEcCtD
Duloxetine—Anaphylactic shock—Methotrexate—lung cancer	0.000128	0.000225	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—lung cancer	0.000128	0.000225	CcSEcCtD
Duloxetine—Asthenia—Docetaxel—lung cancer	0.000127	0.000224	CcSEcCtD
Duloxetine—Infection—Methotrexate—lung cancer	0.000127	0.000223	CcSEcCtD
Duloxetine—Nausea—Etoposide—lung cancer	0.000126	0.000223	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—lung cancer	0.000126	0.000221	CcSEcCtD
Duloxetine—Pruritus—Docetaxel—lung cancer	0.000125	0.00022	CcSEcCtD
Duloxetine—Nervous system disorder—Methotrexate—lung cancer	0.000125	0.00022	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—lung cancer	0.000125	0.00022	CcSEcCtD
Duloxetine—Thrombocytopenia—Methotrexate—lung cancer	0.000125	0.00022	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—lung cancer	0.000124	0.000219	CcSEcCtD
Duloxetine—Nausea—Paclitaxel—lung cancer	0.000124	0.000218	CcSEcCtD
Duloxetine—Skin disorder—Methotrexate—lung cancer	0.000124	0.000218	CcSEcCtD
Duloxetine—Hyperhidrosis—Methotrexate—lung cancer	0.000123	0.000217	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—lung cancer	0.000122	0.000215	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—lung cancer	0.000122	0.000214	CcSEcCtD
Duloxetine—Anorexia—Methotrexate—lung cancer	0.000122	0.000214	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—lung cancer	0.000121	0.000214	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—lung cancer	0.000121	0.000213	CcSEcCtD
Duloxetine—Diarrhoea—Docetaxel—lung cancer	0.000121	0.000213	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—lung cancer	0.00012	0.000211	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—lung cancer	0.000119	0.000209	CcSEcCtD
Duloxetine—Cough—Doxorubicin—lung cancer	0.000118	0.000208	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—lung cancer	0.000117	0.000206	CcSEcCtD
Duloxetine—Dizziness—Docetaxel—lung cancer	0.000117	0.000206	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—lung cancer	0.000117	0.000206	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000116	0.000205	CcSEcCtD
Duloxetine—Insomnia—Methotrexate—lung cancer	0.000115	0.000203	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—lung cancer	0.000115	0.000203	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—lung cancer	0.000115	0.000203	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—lung cancer	0.000115	0.000203	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—lung cancer	0.000115	0.000202	CcSEcCtD
Duloxetine—Paraesthesia—Methotrexate—lung cancer	0.000115	0.000202	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000114	0.000201	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—lung cancer	0.000114	0.0002	CcSEcCtD
Duloxetine—Somnolence—Methotrexate—lung cancer	0.000113	0.0002	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—lung cancer	0.000113	0.000198	CcSEcCtD
Duloxetine—Vomiting—Docetaxel—lung cancer	0.000113	0.000198	CcSEcCtD
Duloxetine—Dyspepsia—Methotrexate—lung cancer	0.000112	0.000198	CcSEcCtD
Duloxetine—Rash—Docetaxel—lung cancer	0.000112	0.000196	CcSEcCtD
Duloxetine—Dermatitis—Docetaxel—lung cancer	0.000111	0.000196	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—lung cancer	0.000111	0.000196	CcSEcCtD
Duloxetine—Decreased appetite—Methotrexate—lung cancer	0.000111	0.000195	CcSEcCtD
Duloxetine—Headache—Docetaxel—lung cancer	0.000111	0.000195	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—lung cancer	0.00011	0.000194	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—lung cancer	0.00011	0.000194	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Methotrexate—lung cancer	0.00011	0.000194	CcSEcCtD
Duloxetine—Fatigue—Methotrexate—lung cancer	0.00011	0.000194	CcSEcCtD
Duloxetine—Infection—Doxorubicin—lung cancer	0.00011	0.000193	CcSEcCtD
Duloxetine—Pain—Methotrexate—lung cancer	0.000109	0.000192	CcSEcCtD
Duloxetine—Shock—Doxorubicin—lung cancer	0.000109	0.000191	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—lung cancer	0.000108	0.000191	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—lung cancer	0.000108	0.00019	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—lung cancer	0.000108	0.00019	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—lung cancer	0.000107	0.000189	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—lung cancer	0.000107	0.000188	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—lung cancer	0.000105	0.000185	CcSEcCtD
Duloxetine—Nausea—Docetaxel—lung cancer	0.000105	0.000185	CcSEcCtD
Duloxetine—Feeling abnormal—Methotrexate—lung cancer	0.000105	0.000185	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methotrexate—lung cancer	0.000104	0.000184	CcSEcCtD
Duloxetine—Urticaria—Methotrexate—lung cancer	0.000101	0.000178	CcSEcCtD
Duloxetine—Body temperature increased—Methotrexate—lung cancer	0.000101	0.000178	CcSEcCtD
Duloxetine—Abdominal pain—Methotrexate—lung cancer	0.000101	0.000178	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000101	0.000177	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—lung cancer	9.99e-05	0.000176	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—lung cancer	9.92e-05	0.000175	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—lung cancer	9.82e-05	0.000173	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—lung cancer	9.72e-05	0.000171	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—lung cancer	9.6e-05	0.000169	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—lung cancer	9.54e-05	0.000168	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—lung cancer	9.52e-05	0.000168	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—lung cancer	9.45e-05	0.000166	CcSEcCtD
Duloxetine—Pain—Doxorubicin—lung cancer	9.45e-05	0.000166	CcSEcCtD
Duloxetine—Hypersensitivity—Methotrexate—lung cancer	9.4e-05	0.000165	CcSEcCtD
Duloxetine—Asthenia—Methotrexate—lung cancer	9.15e-05	0.000161	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—lung cancer	9.1e-05	0.00016	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—lung cancer	9.03e-05	0.000159	CcSEcCtD
Duloxetine—Pruritus—Methotrexate—lung cancer	9.03e-05	0.000159	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—lung cancer	8.77e-05	0.000154	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—lung cancer	8.73e-05	0.000154	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—lung cancer	8.73e-05	0.000154	CcSEcCtD
Duloxetine—Diarrhoea—Methotrexate—lung cancer	8.73e-05	0.000154	CcSEcCtD
Duloxetine—Dizziness—Methotrexate—lung cancer	8.44e-05	0.000148	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—lung cancer	8.14e-05	0.000143	CcSEcCtD
Duloxetine—Vomiting—Methotrexate—lung cancer	8.11e-05	0.000143	CcSEcCtD
Duloxetine—Rash—Methotrexate—lung cancer	8.04e-05	0.000142	CcSEcCtD
Duloxetine—Dermatitis—Methotrexate—lung cancer	8.04e-05	0.000141	CcSEcCtD
Duloxetine—Headache—Methotrexate—lung cancer	7.99e-05	0.000141	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—lung cancer	7.93e-05	0.00014	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—lung cancer	7.81e-05	0.000138	CcSEcCtD
Duloxetine—Nausea—Methotrexate—lung cancer	7.58e-05	0.000133	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—lung cancer	7.56e-05	0.000133	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—lung cancer	7.3e-05	0.000129	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—lung cancer	7.02e-05	0.000124	CcSEcCtD
Duloxetine—Rash—Doxorubicin—lung cancer	6.96e-05	0.000123	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—lung cancer	6.96e-05	0.000122	CcSEcCtD
Duloxetine—Headache—Doxorubicin—lung cancer	6.92e-05	0.000122	CcSEcCtD
Duloxetine—Nausea—Doxorubicin—lung cancer	6.56e-05	0.000115	CcSEcCtD
Duloxetine—CYP2D6—Metabolism—ADCY1—lung cancer	2.55e-05	0.000123	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCG2—lung cancer	2.55e-05	0.000123	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6R—lung cancer	2.54e-05	0.000123	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APC—lung cancer	2.53e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CG—lung cancer	2.53e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KIT—lung cancer	2.53e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—NRAS—lung cancer	2.53e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HES1—lung cancer	2.52e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGF—lung cancer	2.5e-05	0.00012	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ENO2—lung cancer	2.5e-05	0.00012	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HPGDS—lung cancer	2.5e-05	0.00012	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—UGT1A1—lung cancer	2.49e-05	0.00012	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPP2R1B—lung cancer	2.48e-05	0.00012	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RAF1—lung cancer	2.47e-05	0.000119	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FOXO3—lung cancer	2.47e-05	0.000119	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—lung cancer	2.44e-05	0.000118	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTT1—lung cancer	2.42e-05	0.000117	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAP2K1—lung cancer	2.42e-05	0.000117	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK3—lung cancer	2.42e-05	0.000117	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CB—lung cancer	2.41e-05	0.000116	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—lung cancer	2.41e-05	0.000116	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CD—lung cancer	2.41e-05	0.000116	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNG11—lung cancer	2.4e-05	0.000116	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCLC—lung cancer	2.4e-05	0.000115	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2A6—lung cancer	2.4e-05	0.000115	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	2.39e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BRAF—lung cancer	2.38e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6R—lung cancer	2.35e-05	0.000113	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CREBBP—lung cancer	2.34e-05	0.000113	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—lung cancer	2.32e-05	0.000112	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AVP—lung cancer	2.32e-05	0.000112	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CB—lung cancer	2.31e-05	0.000111	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB3—lung cancer	2.31e-05	0.000111	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—lung cancer	2.3e-05	0.000111	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDOA—lung cancer	2.29e-05	0.00011	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ENO1—lung cancer	2.27e-05	0.000109	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAP2K1—lung cancer	2.24e-05	0.000108	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1R—lung cancer	2.23e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CD—lung cancer	2.22e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—lung cancer	2.22e-05	0.000107	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOA3—lung cancer	2.22e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—lung cancer	2.22e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—lung cancer	2.21e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—lung cancer	2.2e-05	0.000106	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HES1—lung cancer	2.19e-05	0.000106	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	2.18e-05	0.000105	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—lung cancer	2.18e-05	0.000105	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADCY1—lung cancer	2.16e-05	0.000104	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCG2—lung cancer	2.16e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RAF1—lung cancer	2.15e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGFR1—lung cancer	2.15e-05	0.000103	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—lung cancer	2.12e-05	0.000102	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HPGDS—lung cancer	2.12e-05	0.000102	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO2—lung cancer	2.12e-05	0.000102	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—lung cancer	2.11e-05	0.000102	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPP2R1B—lung cancer	2.1e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CB—lung cancer	2.1e-05	0.000101	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	2.08e-05	0.0001	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—lung cancer	2.05e-05	9.9e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOA1—lung cancer	2.04e-05	9.83e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2E1—lung cancer	2.04e-05	9.82e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2A6—lung cancer	2.03e-05	9.78e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCLC—lung cancer	2.03e-05	9.78e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	2.02e-05	9.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—lung cancer	2.02e-05	9.74e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—lung cancer	2.01e-05	9.72e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NQO1—lung cancer	2.01e-05	9.71e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB3—lung cancer	2e-05	9.65e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—lung cancer	2e-05	9.64e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MDM2—lung cancer	1.99e-05	9.6e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RAF1—lung cancer	1.98e-05	9.57e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—lung cancer	1.96e-05	9.46e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MTOR—lung cancer	1.94e-05	9.34e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CB—lung cancer	1.94e-05	9.34e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—lung cancer	1.93e-05	9.29e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO1—lung cancer	1.92e-05	9.28e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—lung cancer	1.92e-05	9.25e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.92e-05	9.24e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.89e-05	9.12e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGFR1—lung cancer	1.86e-05	8.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—lung cancer	1.86e-05	8.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APC—lung cancer	1.86e-05	8.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KIT—lung cancer	1.86e-05	8.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—NRAS—lung cancer	1.86e-05	8.98e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—lung cancer	1.86e-05	8.98e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—lung cancer	1.85e-05	8.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGF—lung cancer	1.84e-05	8.87e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—lung cancer	1.83e-05	8.85e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—STK11—lung cancer	1.82e-05	8.75e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—lung cancer	1.8e-05	8.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK3—lung cancer	1.78e-05	8.6e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—lung cancer	1.78e-05	8.59e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—lung cancer	1.78e-05	8.58e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—lung cancer	1.77e-05	8.54e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOA1—lung cancer	1.77e-05	8.54e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—lung cancer	1.77e-05	8.53e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—lung cancer	1.75e-05	8.46e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BRAF—lung cancer	1.75e-05	8.44e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—lung cancer	1.73e-05	8.36e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JUN—lung cancer	1.73e-05	8.34e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6R—lung cancer	1.73e-05	8.33e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CREBBP—lung cancer	1.73e-05	8.32e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2E1—lung cancer	1.73e-05	8.32e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NQO1—lung cancer	1.71e-05	8.23e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—lung cancer	1.7e-05	8.18e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—lung cancer	1.68e-05	8.12e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—lung cancer	1.68e-05	8.1e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1A—lung cancer	1.68e-05	8.09e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—lung cancer	1.67e-05	8.07e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.67e-05	8.06e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.66e-05	7.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAP2K1—lung cancer	1.65e-05	7.94e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CD—lung cancer	1.64e-05	7.89e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAT—lung cancer	1.63e-05	7.88e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—lung cancer	1.63e-05	7.87e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—lung cancer	1.62e-05	7.82e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KIT—lung cancer	1.62e-05	7.79e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—lung cancer	1.62e-05	7.79e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APC—lung cancer	1.62e-05	7.79e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—NRAS—lung cancer	1.62e-05	7.79e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—lung cancer	1.6e-05	7.73e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGF—lung cancer	1.6e-05	7.7e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EP300—lung cancer	1.6e-05	7.7e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCB1—lung cancer	1.59e-05	7.67e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMS—lung cancer	1.56e-05	7.53e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SRC—lung cancer	1.55e-05	7.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK3—lung cancer	1.55e-05	7.46e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—lung cancer	1.54e-05	7.44e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—lung cancer	1.54e-05	7.42e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—STK11—lung cancer	1.54e-05	7.42e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BRAF—lung cancer	1.52e-05	7.33e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—lung cancer	1.51e-05	7.29e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6R—lung cancer	1.5e-05	7.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CREBBP—lung cancer	1.5e-05	7.23e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—lung cancer	1.5e-05	7.22e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRAS—lung cancer	1.49e-05	7.2e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—lung cancer	1.47e-05	7.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—lung cancer	1.47e-05	7.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MDM2—lung cancer	1.47e-05	7.07e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1A1—lung cancer	1.46e-05	7.06e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RAF1—lung cancer	1.46e-05	7.04e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ERCC2—lung cancer	1.45e-05	7e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—lung cancer	1.45e-05	6.97e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.44e-05	6.96e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAP2K1—lung cancer	1.43e-05	6.9e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK3—lung cancer	1.43e-05	6.9e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MTOR—lung cancer	1.43e-05	6.88e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CB—lung cancer	1.43e-05	6.88e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—lung cancer	1.42e-05	6.86e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CD—lung cancer	1.42e-05	6.85e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—lung cancer	1.41e-05	6.79e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—lung cancer	1.39e-05	6.71e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—lung cancer	1.39e-05	6.71e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAT—lung cancer	1.38e-05	6.68e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.38e-05	6.64e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—lung cancer	1.37e-05	6.61e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—lung cancer	1.36e-05	6.57e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—lung cancer	1.36e-05	6.56e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCB1—lung cancer	1.35e-05	6.49e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—lung cancer	1.32e-05	6.39e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMS—lung cancer	1.32e-05	6.38e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—lung cancer	1.31e-05	6.33e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—lung cancer	1.31e-05	6.32e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—lung cancer	1.31e-05	6.3e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—lung cancer	1.3e-05	6.29e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—lung cancer	1.29e-05	6.2e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—lung cancer	1.28e-05	6.16e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—lung cancer	1.28e-05	6.16e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JUN—lung cancer	1.27e-05	6.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MDM2—lung cancer	1.27e-05	6.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RAF1—lung cancer	1.27e-05	6.12e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOA1—lung cancer	1.26e-05	6.05e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—lung cancer	1.26e-05	6.05e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—lung cancer	1.24e-05	5.98e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1A1—lung cancer	1.24e-05	5.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CB—lung cancer	1.24e-05	5.97e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MTOR—lung cancer	1.24e-05	5.97e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1A—lung cancer	1.24e-05	5.96e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—lung cancer	1.23e-05	5.94e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ERCC2—lung cancer	1.23e-05	5.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—lung cancer	1.2e-05	5.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—lung cancer	1.19e-05	5.74e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—lung cancer	1.18e-05	5.7e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—lung cancer	1.18e-05	5.69e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EP300—lung cancer	1.18e-05	5.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—lung cancer	1.15e-05	5.54e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—lung cancer	1.15e-05	5.53e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SRC—lung cancer	1.14e-05	5.51e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—lung cancer	1.14e-05	5.51e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—lung cancer	1.14e-05	5.49e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—lung cancer	1.14e-05	5.49e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—lung cancer	1.13e-05	5.46e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—lung cancer	1.11e-05	5.37e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—lung cancer	1.11e-05	5.35e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JUN—lung cancer	1.11e-05	5.34e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—lung cancer	1.1e-05	5.32e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRAS—lung cancer	1.1e-05	5.3e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—lung cancer	1.09e-05	5.27e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—lung cancer	1.09e-05	5.26e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—lung cancer	1.08e-05	5.19e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1A—lung cancer	1.07e-05	5.17e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—lung cancer	1.07e-05	5.16e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA1—lung cancer	1.06e-05	5.13e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CREBBP—lung cancer	1.06e-05	5.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK3—lung cancer	1.05e-05	5.08e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—lung cancer	1.05e-05	5.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—lung cancer	1.04e-05	5.04e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—lung cancer	1.02e-05	4.94e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EP300—lung cancer	1.02e-05	4.92e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.02e-05	4.91e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CD—lung cancer	1.01e-05	4.86e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—lung cancer	1e-05	4.83e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—lung cancer	9.95e-06	4.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SRC—lung cancer	9.93e-06	4.79e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—lung cancer	9.71e-06	4.68e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—lung cancer	9.67e-06	4.66e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—lung cancer	9.65e-06	4.65e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—lung cancer	9.57e-06	4.62e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRAS—lung cancer	9.55e-06	4.6e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—lung cancer	9.46e-06	4.56e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—lung cancer	9.24e-06	4.46e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK3—lung cancer	9.15e-06	4.41e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CREBBP—lung cancer	9e-06	4.34e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—lung cancer	8.89e-06	4.29e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CB—lung cancer	8.78e-06	4.23e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—lung cancer	8.7e-06	4.2e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—lung cancer	8.7e-06	4.2e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—lung cancer	8.7e-06	4.19e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CD—lung cancer	8.54e-06	4.12e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—lung cancer	8.43e-06	4.06e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—lung cancer	8.41e-06	4.06e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—lung cancer	8.22e-06	3.96e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—lung cancer	8.04e-06	3.88e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—lung cancer	7.7e-06	3.71e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—lung cancer	7.59e-06	3.66e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—lung cancer	7.55e-06	3.64e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CB—lung cancer	7.44e-06	3.59e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—lung cancer	7.37e-06	3.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—lung cancer	7.3e-06	3.52e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—EP300—lung cancer	7.24e-06	3.49e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—lung cancer	7.1e-06	3.43e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—lung cancer	6.99e-06	3.37e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—lung cancer	6.69e-06	3.22e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—lung cancer	6.43e-06	3.1e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—lung cancer	6.17e-06	2.97e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—EP300—lung cancer	6.13e-06	2.96e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—lung cancer	5.35e-06	2.58e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—lung cancer	4.54e-06	2.19e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—lung cancer	4.37e-06	2.11e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—lung cancer	3.7e-06	1.79e-05	CbGpPWpGaD
